TAGWORKSPHARMA.COM: Keyword Density Checker

Total words: 1508 | 2-word phrases: 401 | 3-word phrases: 422 | 4-word phrases: 427

PAGE INFO

Title	Try to keep the title under 60 characters (55 characters) Pioneers of Click-to-Release - Tagworks Pharmaceuticals
Description	Try to keep the meta description between 50 - 160 characters (178 characters) As pioneers of Click-to-Release technology, we are revolutionizing cancer treatment using in vivo click chemistry to increase the therapeutic window of powerful cancer therapies.
Keywords	Meta keywords are not recommended anymore (0 characters)
H1	H1 tag on the page (10 characters) Team works

#	Keyword	Frequency	Density
1	enables controlled drug	2	0.47%
2	radiotherapeutics program at	2	0.47%
3	activation of antibodydrug	2	0.47%
4	of antibodydrug conjugates	2	0.47%
5	in vivo click	2	0.47%
6	october 1 2024	2	0.47%
7	unique clicktorelease platform	1	0.24%
8	tgw101 is a	1	0.24%
9	program tgw101 is	1	0.24%
10	lead program tgw101	1	0.24%
11	our lead program	1	0.24%
12	ventures unique clicktorelease	1	0.24%
13	june 22 2023	1	0.24%
14	heterogenous target expression	1	0.24%
15	with heterogenous target	1	0.24%
16	a clickcleavable adc	1	0.24%
17	tumors with heterogenous	1	0.24%
18	kill tumors with	1	0.24%
19	to kill tumors	1	0.24%
20	possible to kill	1	0.24%
21	is a clickcleavable	1	0.24%
22	adc targeting tag72	1	0.24%
23	clickcleavable adc targeting	1	0.24%
24	is widely expressed	1	0.24%
25	so far remained	1	0.24%
26	has so far	1	0.24%
27	which has so	1	0.24%
28	but which has	1	0.24%
29	tumors but which	1	0.24%
30	solid tumors but	1	0.24%

#	Keyword	Frequency	Density
1	activation of antibodydrug conjugates	2	0.47%
2	type and cancer cell	1	0.23%
3	to suitable internalizing targets	1	0.23%
4	suitable internalizing targets which	1	0.23%
5	fund new enterprise associates	1	0.23%
6	venture fund new enterprise	1	0.23%
7	novartis venture fund new	1	0.23%
8	are not necessarily expressed	1	0.23%
9	not necessarily expressed by	1	0.23%
10	necessarily expressed by every	1	0.23%
11	expressed by every cancer	1	0.23%
12	by every cancer type	1	0.23%
13	every cancer type and	1	0.23%
14	cancer type and cancer	1	0.23%
15	and cancer cell we	1	0.23%
16	are limited to suitable	1	0.23%
17	from novartis venture fund	1	0.23%
18	participation from novartis venture	1	0.23%
19	appoints ken mills as	1	0.23%
20	are leveraging our clicktorelease	1	0.23%
21	leveraging our clicktorelease approach	1	0.23%
22	our clicktorelease approach to	1	0.23%
23	clicktorelease approach to expand	1	0.23%
24	approach to expand the	1	0.23%
25	to expand the adc	1	0.23%
26	expand the adc target	1	0.23%
27	pharmaceuticals appoints ken mills	1	0.23%
28	tagworks pharmaceuticals appoints ken	1	0.23%
29	limited to suitable internalizing	1	0.23%
30	adcs are limited to	1	0.23%
31	scope to non or	1	0.23%
32	as the offtarget deactivation	1	0.23%
33	of antibodydrug conjugates adcs	1	0.23%
34	antibodydrug conjugates adcs and	1	0.23%
35	conjugates adcs and immunomodulators	1	0.23%
36	adcs and immunomodulators in	1	0.23%
37	to lead tagworks as	1	0.23%
38	veteran to lead tagworks	1	0.23%
39	industry veteran to lead	1	0.23%
40	the tumor microenvironment as	1	0.23%

#	URL	Whois	Check
1	https://www.apetozebra.com	Whois	apetozebra.com